Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda Qlex
pembrolizumab + berahyaluronidase alfa-pmph · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous treatment for adults and children age 12 years or older with unresectable or metastatic solid tumors that are TMB-high (at least 10 mutations per megabase) by an FDA-approved test, after progression on prior treatment with no satisfactory alternatives.
LAMPGEN ANALYSIS
Why it matters
The new formulation carried a distinct accelerated approval for the tumor-agnostic TMB-high use.
What research teams should watch
Use the correct tumor mutational burden assay and threshold and keep the formulation-specific indication linked to its confirmatory status.
PRIMARY RECORDS